Fig. 6From: Downregulated TICAM1 is a prognostic biomarker and associated with immune tolerance of Wilms tumor patientsDistribution of IC50 scores. Cisplatin (A), Doxorubicin (B), Etoposide (C), Sorafenib (D), Vinblastine (E), Vinorelbine (F)Back to article page